HRP940967B1 - Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl) 1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate - Google Patents

Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl) 1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate

Info

Publication number
HRP940967B1
HRP940967B1 HRP4424677.3A HRP940967A HRP940967B1 HR P940967 B1 HRP940967 B1 HR P940967B1 HR P940967 A HRP940967 A HR P940967A HR P940967 B1 HRP940967 B1 HR P940967B1
Authority
HR
Croatia
Prior art keywords
methoxyethyl
dihydro
chloro
isopropyl
piridine
Prior art date
Application number
HRP4424677.3A
Other languages
English (en)
Inventor
Teunis Schuurman
Original Assignee
Teunis Schuurman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4342194A external-priority patent/DE4342194A1/de
Priority claimed from DE19944424677 external-priority patent/DE4424677A1/de
Application filed by Teunis Schuurman filed Critical Teunis Schuurman
Publication of HRP940967A2 publication Critical patent/HRP940967A2/hr
Publication of HRP940967B1 publication Critical patent/HRP940967B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
HRP4424677.3A 1993-12-10 1994-12-01 Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl) 1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate HRP940967B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4342194A DE4342194A1 (de) 1993-12-10 1993-12-10 Halogen-phenyl-substituierte 1,4-Dihydropyridine
DE19944424677 DE4424677A1 (de) 1994-07-13 1994-07-13 Isopropyl-(2-methoxyethyl)-4-(2-chlor-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridin-3,5-dicarboxylat

Publications (2)

Publication Number Publication Date
HRP940967A2 HRP940967A2 (en) 1997-08-31
HRP940967B1 true HRP940967B1 (en) 1999-12-31

Family

ID=25931956

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP4424677.3A HRP940967B1 (en) 1993-12-10 1994-12-01 Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl) 1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate

Country Status (35)

Country Link
US (1) US5665740A (xx)
EP (1) EP0657430B1 (xx)
JP (1) JP3751041B2 (xx)
KR (1) KR100332325B1 (xx)
CN (2) CN1056606C (xx)
AT (1) ATE180774T1 (xx)
AU (1) AU686976B2 (xx)
BG (1) BG62487B1 (xx)
CA (1) CA2137525C (xx)
CO (1) CO4290426A1 (xx)
CU (1) CU22713A3 (xx)
CZ (1) CZ286065B6 (xx)
DE (1) DE59408350D1 (xx)
DK (1) DK0657430T3 (xx)
DZ (1) DZ1831A1 (xx)
EE (1) EE03192B1 (xx)
ES (1) ES2132308T3 (xx)
FI (1) FI105681B (xx)
GR (1) GR3030436T3 (xx)
HR (1) HRP940967B1 (xx)
HU (1) HU215593B (xx)
IL (1) IL111922A (xx)
LV (1) LV11321B (xx)
MA (1) MA23392A1 (xx)
MY (1) MY111976A (xx)
NO (1) NO302362B1 (xx)
NZ (1) NZ270087A (xx)
PL (1) PL179973B1 (xx)
RO (1) RO115800B1 (xx)
SA (1) SA95160078B1 (xx)
SK (1) SK282399B6 (xx)
SV (1) SV1994000072A (xx)
TN (1) TNSN94127A1 (xx)
TW (1) TW412529B (xx)
YU (1) YU48920B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153953A1 (en) * 2003-11-21 2005-07-14 Crista Trippodi-Murphy Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
WO2019104041A1 (en) * 2017-11-21 2019-05-31 Michael Ohlmeyer Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3932646A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3239273A1 (de) * 1982-10-23 1984-04-26 Bayer Ag, 5090 Leverkusen Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
DE3718398A1 (de) * 1987-06-02 1988-12-22 Troponwerke Gmbh & Co Kg Neue kombinationspraeparate mit antidepressiver wirkung
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
DE3806277A1 (de) * 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
FR2671349B1 (fr) * 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester

Also Published As

Publication number Publication date
EP0657430B1 (de) 1999-06-02
NZ270087A (en) 1996-08-27
RO115800B1 (ro) 2000-06-30
IL111922A0 (en) 1995-03-15
SK151694A3 (en) 1995-07-11
AU8030694A (en) 1995-06-15
SV1994000072A (es) 1995-08-09
DK0657430T3 (da) 1999-11-15
FI105681B (fi) 2000-09-29
BG62487B1 (bg) 1999-12-30
ES2132308T3 (es) 1999-08-16
CA2137525C (en) 2005-07-12
DE59408350D1 (de) 1999-07-08
LV11321B (en) 1996-12-20
MA23392A1 (fr) 1995-07-01
GR3030436T3 (en) 1999-09-30
YU48920B (sh) 2002-11-15
YU71794A (sh) 1996-10-18
CN1244525A (zh) 2000-02-16
PL306157A1 (en) 1995-06-12
JPH07242632A (ja) 1995-09-19
KR950017958A (ko) 1995-07-22
CN1056606C (zh) 2000-09-20
HUT70937A (en) 1995-11-28
CZ309394A3 (en) 1995-11-15
KR100332325B1 (ko) 2002-09-04
FI945777A0 (fi) 1994-12-08
HRP940967A2 (en) 1997-08-31
DZ1831A1 (fr) 2002-02-17
ATE180774T1 (de) 1999-06-15
NO944787D0 (no) 1994-12-09
JP3751041B2 (ja) 2006-03-01
MY111976A (en) 2001-03-31
CN1124258C (zh) 2003-10-15
NO944787L (no) 1995-06-12
CN1109874A (zh) 1995-10-11
IL111922A (en) 1999-05-09
LV11321A (lv) 1996-06-20
NO302362B1 (no) 1998-02-23
TNSN94127A1 (en) 1995-09-21
HU215593B (hu) 1999-01-28
CO4290426A1 (es) 1996-04-17
TW412529B (en) 2000-11-21
CU22713A3 (es) 1996-07-05
SA95160078B1 (ar) 2006-09-25
PL179973B1 (pl) 2000-11-30
EP0657430A1 (de) 1995-06-14
CA2137525A1 (en) 1995-06-11
EE03192B1 (et) 1999-06-15
CZ286065B6 (cs) 2000-01-12
HU9403551D0 (en) 1995-02-28
SK282399B6 (sk) 2002-01-07
AU686976B2 (en) 1998-02-12
US5665740A (en) 1997-09-09
FI945777A (fi) 1995-06-11
BG99249A (en) 1995-09-29

Similar Documents

Publication Publication Date Title
CA2142610A1 (en) Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
FR2691065B1 (fr) Nouvelles compositions oculaires destinees a la prevention et au traitement de certains troubles de la vision.
HUP9900927A3 (en) Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GR3030436T3 (en) Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate.
ZA906057B (en) 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
ZA942883B (en) Condensed quinolyl-dihydropyridines processes for their preparation and their use in medicaments
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
NO993126D0 (no) Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner
EP0432751A3 (en) Isomers of 1-azabicyclo(2.2.2)oct-3-yl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-nitropyridine-3-carboxylate
PT80521B (en) Process for the preparation of esters of the 1,4-dihydro-2,6-dimethyl-3-(alcoxicarbonyl or alcoxialcoxicarbonyl)-4-(substituted phenyl) pyridin-5-carboxylic acid of stereochemical isomers and pharmaceutically acceptable salts thereof
SE9203857D0 (sv) Use of an enantiomeric dihydropyridine
AU636488C (en) Use of a 1-2(-naphthylethyl)-4-(3-trifluoromethylphenyl)-1, 2,3,6-tetrahydropyridine for the treatment of cerebral and n euronal diseases

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20101118

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20111202